润都股份：三季度雷贝拉唑肠溶胶囊销售同比基本持平

Core Viewpoint - The company, Rundu Co., has indicated that its sales of Rabeprazole Sodium Enteric-coated Capsules will significantly decline in 2024 due to the impact of the ninth batch of national drug procurement, which will adversely affect its performance in 2024 and the first half of 2025 [1] Group 1 - The sales volume of Rabeprazole Sodium Enteric-coated Capsules is expected to drop substantially in 2024 [1] - The performance impact is anticipated to be significant for both 2024 and the first half of 2025 [1] - By the third quarter of 2025, sales of the product are projected to be roughly in line with the same period last year [1] Group 2 - The company highlights the good clinical efficacy and market reputation of the product, suggesting a potential recovery in market size in the future [1]